Title: Innovations of Jing-Jing Tang in Pharmaceutical Research
Introduction
Jing-Jing Tang is a notable inventor based in China, recognized for his contributions to pharmaceutical research. He has focused on developing compositions that target amyloid beta peptide-associated diseases. Despite having no patents registered under his name, his work has significant implications in the field of medicine.
Latest Patents
Jing-Jing Tang's latest patents include a pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions. This composition contains isoacteoside, which is effective in inhibiting the formation, accumulation, or aggregation of amyloid beta peptides. The weight ratio of isoacteoside to acteoside in this composition ranges from 4:1 to 1:4. Another significant patent involves the use of isoacteoside or its pharmaceutically acceptable salt as an inhibitor of the production, accumulation, or aggregation of amyloid beta peptide, which is crucial for preventing or treating related diseases or symptoms.
Career Highlights
Jing-Jing Tang is currently associated with Sinphar Tian-li Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His research is pivotal in addressing critical health issues related to amyloid beta peptides.
Collaborations
Jing-Jing Tang has collaborated with notable colleagues, including Hang-Ching Lin and Muh-Hwan Su, to advance his research and development efforts.
Conclusion
Jing-Jing Tang's work in pharmaceutical innovation, particularly concerning amyloid beta peptide-associated diseases, showcases his commitment to improving health outcomes. His contributions, although not yet reflected in patents, hold promise for future advancements in medicine.